Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
3/10/25 Mineralys (MLYS) Lorundrostat for Hypertension (Systemic) Subscribers Only Subscribers Only Subscribers Only
3/10/25 Mineralys (MLYS) Lorundrostat for Hypertension (Systemic) Subscribers Only Subscribers Only Subscribers Only
3/6/25 ITM EndolucinBeta for Neuroendocrine Tumors (NET) Subscribers Only Subscribers Only Subscribers Only
3/6/25 Medicus Pharma (MDCX) D-MNA for Skin Cancer - Basal Cell Carcinoma (BCC) Subscribers Only Subscribers Only Subscribers Only
3/3/25 Biomed NA-921 for Rett Syndrome Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
12/31/2024 Subscribers Only Subscribers Only Regulatory - IND/CTA Filing
02/12/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
02/12/2025 Subscribers Only Subscribers Only Trial Data - Updated Results
02/27/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
03/05/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update